title: Restless legs syndrome improved by pramipexole: a double-blind randomized trial.
abstract: BACKGROUND
  Restless legs syndrome (RLS) is characterized by leg paresthesia associated with an irresistible urge to move. Currently used dopaminergic agents, such as levodopa, pergolide, and bromocriptine, offer incomplete control of sensory and motor symptoms and induce severe side effects.
  
  
  OBJECTIVE
  To assess the safety and efficacy of pramipexole, a full D3-receptor agonist, in the treatment of RLS.
  
  
  METHODS
  Ten RLS patients were studied before and after two 1-month treatments (placebo and pramipexole) administered in a double-blind crossover fashion. The severity of sensory and motor manifestations was assessed by 1 week of home questionnaires and 2 consecutive nights of sleep laboratory recordings. The indexes of periodic leg movement during sleep (PLMS) and during wakefulness (PLMW) were used as primary outcome variables.
  
  
  RESULTS
  Pramipexole dramatically reduced the PLMS index to normal values (Wilcoxon, p = 0.005). The PLMW index was also significantly reduced (Wilcoxon, p = 0.007). Pramipexole also alleviated leg discomfort at bedtime and during the night as measured by the home questionnaires.
  
  
  CONCLUSIONS
  Pramipexole is the most potent therapeutic agent ever tested for RLS. Measures of both sensory and motor functions returned to normal values after treatment. Moreover, these results further support the hypothesis that D3 receptors play a major role in the physiopathology of this condition.
authors: Centre d'Etude du Sommeil, Hôpital du Sacré-Coeur de Montréal, Québec, Canada.
authors: J
authors: J
authors: Montplaisir
authors: A
authors: A
authors: Nicolas
authors: R
authors: R
authors: Denesle
authors: B
authors: B
authors: Gomez-Mancilla
mesh_terms: D000328:Adult; D052160:Benzothiazoles; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077487:Pramipexole; D012148:Restless Legs Syndrome / Q000188:drug therapy*; D013577:Syndrome; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D052160:Benzothiazoles; D018491:Dopamine Agonists; D013844:Thiazoles; D000077487:Pramipexole